AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

30 years of HER3: From basic biology to therapeutic interventions

(2021) Heidi M. Haikala et al.   CLINICAL CANCER RESEARCH

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer

(2020) Nellie K McDaniel et al.   CLINICAL CANCER RESEARCH

Inhibition of tumor cell growth and cancer stem cell expansion by a bispecific antibody targeting EGFR and HER3

(2020) Alexander Rau et al.   MOLECULAR CANCER THERAPEUTICS

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) David G. Pfister et al.   Journal of the National Comprehensive Cancer Network

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

(2020) Wen-Qi Cai et al.   Frontiers in Oncology

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

(2020) Claudia Cardone et al.   EUROPEAN JOURNAL OF CANCER

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

(2019) Hirokazu Taniguchi et al.   Nature Communications

Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

(2019) Xiaolong Liu et al.   BIOLOGICAL PROCEDURES ONLINE

Neuregulin Signaling is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

(2019) Marta Baro et al.   MOLECULAR CANCER THERAPEUTICS

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

(2019) Chenjing Zhu et al.   Molecular Cancer

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study

(2019) Martin D. Forster et al.   EUROPEAN JOURNAL OF CANCER

Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer

(2018) Charline Ogier et al.   CANCER LETTERS

BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC

(2018) Brandon Leonard et al.   CANCER RESEARCH

Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers

(2018) Alexander Drilon et al.   Cancer Discovery

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents

(2018) Nellie K McDaniel et al.   MOLECULAR CANCER THERAPEUTICS

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells

(2018) Kei Namba et al.   MOLECULAR CANCER RESEARCH

Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC

(2017) Adam D. Swick et al.   MOLECULAR CANCER THERAPEUTICS

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC

(2017) Diego Alvarado et al.   PLoS One

Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer

(2016) Shi Hu et al.   CANCER LETTERS

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

(2016) Dongsheng Wang et al.   CLINICAL CANCER RESEARCH

Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas

(2016) Bénédicte Rysman et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

(2016) M. Iida et al.   MOLECULAR CANCER THERAPEUTICS

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

(2016) Jérôme Fayette et al.   Frontiers in Oncology

Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models

(2015) D. M. Francis et al.   CLINICAL CANCER RESEARCH

Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies

(2015) N. I. Pollock et al.   CLINICAL CANCER RESEARCH

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma

(2015) T. M. Brand et al.   CLINICAL CANCER RESEARCH

Targeting HER (ERBB) signaling in head and neck cancer: An essential update

(2015) Jun Zhang et al.   MOLECULAR ASPECTS OF MEDICINE

Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration

(2015) Sangwon Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

(2015) Hisato Kawakami et al.   Oncotarget

AXL Mediates Resistance to Cetuximab Therapy

(2014) T. M. Brand et al.   CANCER RESEARCH

Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models

(2014) K. Meetze et al.   CLINICAL CANCER RESEARCH

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

(2014) Mari Iida et al.   Molecular Cancer

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

(2014) C. Feneyrolles et al.   MOLECULAR CANCER THERAPEUTICS

Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy

(2014) Robert Torka et al.   NEOPLASIA

MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation

(2013) J. K. Rho et al.   CANCER RESEARCH

Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

(2013) Keith M. Giles et al.   MOLECULAR CANCER THERAPEUTICS

Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non-Small Cell Lung Cancer

(2013) G. V. Hegde et al.   Science Translational Medicine

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation

(2012) S. Huang et al.   CANCER RESEARCH

Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts

(2012) R. J. Kimple et al.   CLINICAL CANCER RESEARCH

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer

(2012) R M A Linger et al.   ONCOGENE

Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma

(2011) Mikiko Takikita et al.   Journal of Translational Medicine

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

(2010) X Ye et al.   ONCOGENE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE